EUSA Pharma (UK) Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From EUSA Pharma (UK) Ltd.
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
Despite multiple challenges including pricing pressures and slowing general economic growth, China offers attractive opportunities for emerging biopharma firms, helped by an encouraging regulatory environment. But weighing up options around challenging areas including partnering is essential, a new report states.
Keeping Track: US FDA Approval Of Jazz Rylaze Addresses Shortage; MediWound, Cyclopharm Receive CRLs
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
The Beijing/Boston-based bioventure shocked the industry with its recent announcement of the return of exclusive rights to an oncology assets in the greater China area to its US licensee, in an effort to focus squarely on rare diseases. CEO James Xue shares his views on this market in China in an exclusive interview with Scrip.
- Medical Devices
- Specialty Pharmaceuticals
- Large Molecule